Johnson & Johnson Announced At ESMO Saturday, Phase 3 PROTEUS Substudy Data Showing Perioperative Apalutamide Plus ADT Reduced Risk Of Disease Recurrence Or Death By 62%, Metastasis Or Death By 51% Vs. Surgery Alone In High-Risk Prostate Cancer
Share
Why It Matters
Johnson & Johnson announced that a cancer medicine tested with surgery worked really well. This positive research result shows the company is making progress on an important treatment.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.